David Michael Holtzman, MD

• C2N Diagnostics
• Royalties: $1 - $9,999
• Equity: Yes
• Consulting/Advisory Board: $40,000 - $59,999
• Reporting Date: 05/01/2024

• Cajal Neuroscience
• Consulting/Advisory Board: $20,000 - $39,999
• Reporting Date: 05/01/2024

• Denali
• Consulting/Advisory Board: $10,000 - $19,999
• Reporting Date: 05/01/2024

• Genentech
• Consulting/Advisory Board: $20,000 - $39,999
• Reporting Date: 05/01/2024

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.